WallStSmart

Merck & Company Inc (MRK)vsSmith & Nephew SNATS Inc (SNN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 967% more annual revenue ($65.77B vs $6.16B). MRK leads profitability with a 13.6% profit margin vs 10.1%. SNN appears more attractively valued with a PEG of 1.27. SNN earns a higher WallStSmart Score of 60/100 (C+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

SNN

Buy

60

out of 100

Grade: C+

Growth: 7.3Profit: 6.5Value: 5.7Quality: 7.0
Piotroski: 5/9Altman Z: 2.52
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for SNN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

SNN1 strengths · Avg: 10.0/10
EPS GrowthGrowth
70.4%10/10

Earnings expanding 70.4% YoY

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SNN1 concerns · Avg: 4.0/10
Price/BookValuation
12.3x4/10

Trading at 12.3x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : SNN

The strongest argument for SNN centers on EPS Growth. PEG of 1.27 suggests the stock is reasonably priced for its growth.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : SNN

The primary concerns for SNN are Price/Book.

Key Dynamics to Monitor

SNN carries more volatility with a beta of 0.67 — expect wider price swings.

SNN is growing revenue faster at 7.4% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SNN scores higher overall (60/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Smith & Nephew SNATS Inc

HEALTHCARE · MEDICAL DEVICES · USA

Smith & Nephew plc develops, manufactures, markets and sells medical devices worldwide. The company is headquartered in Watford, the United Kingdom.

Visit Website →

Want to dig deeper into these stocks?